choline has been researched along with Clerambault Syndrome in 8 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "There are no specific biological treatments for FASDs, but rodent models have shown that prenatal or postnatal choline supplementation reduces cognitive and behavioral deficits." | 2.80 | Choline supplementation in children with fetal alcohol spectrum disorders: a randomized, double-blind, placebo-controlled trial. ( Boys, CJ; Brearley, AM; Eckerle, JK; Fink, BA; Fuglestad, AJ; Georgieff, MK; Hoecker, HL; Kroupina, MG; Miller, NC; Radke, JP; Wozniak, JR; Zeisel, SH, 2015) |
| "Choline (5ppm) was given to half the nursing dams and weanlings in each group from P11-P30." | 1.48 | Beneficial effects of postnatal choline supplementation on long-Term neurocognitive deficit resulting from fetal-Neonatal iron deficiency. ( Georgieff, MK; Gewirtz, JC; Kennedy, BC; Kohli, M; Maertens, JJ; Tran, PV, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kennedy, BC | 1 |
| Tran, PV | 1 |
| Kohli, M | 1 |
| Maertens, JJ | 1 |
| Gewirtz, JC | 1 |
| Georgieff, MK | 2 |
| Wozniak, JR | 1 |
| Fuglestad, AJ | 1 |
| Eckerle, JK | 1 |
| Fink, BA | 1 |
| Hoecker, HL | 1 |
| Boys, CJ | 1 |
| Radke, JP | 1 |
| Kroupina, MG | 1 |
| Miller, NC | 1 |
| Brearley, AM | 1 |
| Zeisel, SH | 1 |
| Fukuzako, H | 1 |
| Takeuchi, K | 2 |
| Hokazono, Y | 1 |
| Fukuzako, T | 2 |
| Yamada, K | 2 |
| Hashiguchi, T | 1 |
| Obo, Y | 1 |
| Ueyama, K | 1 |
| Takigawa, M | 1 |
| Fujimoto, T | 2 |
| Nakano, T | 1 |
| Takano, T | 1 |
| Akimoto, H | 1 |
| Sibbitt, WL | 1 |
| Haseler, LJ | 1 |
| Griffey, RR | 1 |
| Friedman, SD | 1 |
| Brooks, WM | 1 |
| McConnell, HW | 1 |
| Mitchell, SC | 1 |
| Smith, RL | 1 |
| Brewster, M | 1 |
| Kinney, DK | 1 |
| Steingard, RJ | 1 |
| Renshaw, PF | 1 |
| Yurgelun-Todd, DA | 1 |
| Domino, EF | 1 |
| Krause, RR | 1 |
| Bowers, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Postnatal Choline Supplementation in Children With Prenatal Alcohol Exposure[NCT01149538] | Phase 1/Phase 2 | 60 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| Libman-Sacks Endocarditis as a Cause of Neuropsychiatric Systemic Lupus Erythematosus[NCT00858884] | 68 participants (Actual) | Interventional | 2006-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Elicited Imitation (EI) paradigm (P.J. Bauer, 1989, Dev. Psychology) was used to measure memory in the participants at baseline, 6 months, and 9 months. The measures were items recalled after a delay (delayed items) and pairs of items recalled after a delay (delayed pairs). The sample was split by age in the analysis (young vs. old) as reflected in the outcome data. Outcome data measures included here are the slopes of the regression lines reflecting change over the three timepoints, controlling for immediate memory performance on the EI task.The slopes are given, as opposed to the raw scores, because these were the values used in the growth curve analyses. Details of these analyses are included in Wozniak et al. (2015) AJCN, doi:10.3945/ajcn.114.099168. NOTE that the means presented below represent the simple slopes that estimate the change in task performance (% of items correct) per 6-month unit of time. To estimate change in task performance over 9 months, multiply by 1.5. (NCT01149538)
Timeframe: Baseline, 6 months, and 9 months
| Intervention | Slope (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Delayed-Items-Young | Delayed-Items-Old | Delayed-Pairs-Young | Delayed-Pairs-Old | Immed-Items-Young | Immed-Items-Old | Immed-Pairs-Young | Immed-Pairs-Old | |
| Choline Bitartrate | 14.24 | -.71 | 18.97 | 2.69 | 8.48 | 2.59 | 8.75 | 11.46 |
| Placebo | 4.43 | 4.23 | 10.39 | 7.79 | 13.72 | 3.89 | 20.01 | 5.50 |
Evoked Response Potential - negative component latency data are included. (NCT01149538)
Timeframe: Baseline, 6 months, and 9 months
| Intervention | Milliseconds (Mean) | ||
|---|---|---|---|
| Frontal Neg Component Latency at baseline | Frontal Neg Component at 6 months | Frontal Neg Component at 9 months | |
| Choline Bitartrate | 2.23 | 32.45 | -4.00 |
| Placebo | 5.35 | -4.28 | -3.03 |
Evoked response potentials were measured for the memory task. Frontal positive slow-wave potential negative component amplitude data are included. (NCT01149538)
Timeframe: Baseline, 6 months, and 9 months
| Intervention | Mircovolts (Mean) | |||||
|---|---|---|---|---|---|---|
| Frontal Positive Slow Wave (PSW) - Baseline | Frontal Positive Slow Wave (PSW) - 6 months | Frontal Positive Slow Wave (PSW) - 9 months | Frontal Neg Component Amplitude - Baseline | Frontal Neg Component Amplitude - 6 months | Frontal Neg Component Amplitude - 9 months | |
| Choline Bitartrate | -2.05 | -1.04 | -0.26 | -2.53 | 1.22 | 0.35 |
| Placebo | 0.57 | -1.03 | -1.41 | 0.62 | -0.84 | -1.37 |
The Mullen Scales of Early Learning is a measure of global cognitive development and is a primary outcome measure. The Early Learning Composite is the total score for this measure. It is a scaled score with a mean of 100 and a standard deviation of 15 (higher scores indicate better global cognitive status; average range is 85-115; Impaired range is 70 or below; full range is typically 50 - 150, although minimum and maximum scores are dependent on age). See the Mullen Scales reference manual for more psychometric details. (NCT01149538)
Timeframe: Baseline and 9 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 9-month follow-up | |
| Choline Bitartrate | 83.2 | 87.1 |
| Placebo | 84.3 | 89.6 |
Side effects of choline bitartrate will be monitored by the study physician and the P.I. with physical examinations and telephone contact. (NCT01149538)
Timeframe: Baseline, 6 months, & 9 months
| Intervention | participants (Number) | ||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline energy level problems | 6 month energy level problems | 9 months energy level problems | Baseline pain | 6 month pain | 9 month pain | Baseline skin problems | 6 month skin problems | 9 month skin problems | Baseline Ear Nose Throat problems | 6 month Ear Nose Throat problems | 9 month Ear Nose Throat problems | Baseline headaches/dizziness | 6 month headaches/dizziness | 9 month headaches/dizziness | Baseline vision problems | 6 month vision problems | 9 month vision problems | Baseline cardiovascular | 6 month cardiovascular | 9 month cardiovascular | Baseline respiratory problems | 6 month respiratory problems | 9 month respiratory problems | Baseline gastrointestinal problems | 6 month gastrointestinal problems | 9 month gastrointestinal problems | Baseline genitourinary problems | 6 month genitourinary problems | 9 month genitourinary problems | Baseline musculoskeletal problems | 6 month musculoskeletal problems | 9 month musculoskeletal problems | 6 month neurologic/psychiatric problems | 9 month neurologic/psychiatric problems | Baseline neurologic/psychiatric problems | Baseline allergic problems | 6 month allergic problems | 9 month allergic problems | |
| Choline Bitartrate | 8 | 8 | 8 | 3 | 3 | 3 | 6 | 6 | 6 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 0 | 0 | 1 | 1 | 1 | 6 | 6 | 6 | 18 | 18 | 18 | 4 | 4 | 4 | 0 | 0 | 0 | 11 | 11 | 11 | 2 | 0 | 0 |
| Placebo | 10 | 9 | 9 | 4 | 4 | 4 | 6 | 5 | 5 | 0 | 0 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 6 | 6 | 6 | 14 | 11 | 11 | 9 | 8 | 8 | 1 | 1 | 1 | 9 | 9 | 9 | 3 | 3 | 3 |
1 trial available for choline and Clerambault Syndrome
| Article | Year |
|---|---|
Choline supplementation in children with fetal alcohol spectrum disorders: a randomized, double-blind, placebo-controlled trial.
Topics: Behavioral Symptoms; Child, Preschool; Choline; Dietary Supplements; Double-Blind Method; Feasibilit | 2015 |
7 other studies available for choline and Clerambault Syndrome
| Article | Year |
|---|---|
Beneficial effects of postnatal choline supplementation on long-Term neurocognitive deficit resulting from fetal-Neonatal iron deficiency.
Topics: Anemia, Iron-Deficiency; Animals; Animals, Newborn; Choline; Dietary Supplements; Female; Hippocampu | 2018 |
Proton magnetic resonance spectroscopy of the left medial temporal and frontal lobes in chronic schizophrenia: preliminary report.
Topics: Adult; Arousal; Aspartic Acid; Choline; Creatine; Dominance, Cerebral; Energy Metabolism; Female; Fr | 1995 |
Proton magnetic resonance spectroscopy of basal ganglia in chronic schizophrenia.
Topics: Adult; Aspartic Acid; Basal Ganglia; Basal Ganglia Diseases; Brain Mapping; Choline; Chronic Disease | 1996 |
Neurometabolism of active neuropsychiatric lupus determined with proton MR spectroscopy.
Topics: Adult; Aspartic Acid; Brain; Brain Damage, Chronic; Brain Ischemia; Brain Mapping; Choline; Creatine | 1997 |
Trimethylaminuria associated with seizures and behavioural disturbance: a case report.
Topics: Adolescent; Child; Child Behavior Disorders; Choline; Diagnosis, Differential; Epilepsy, Complex Par | 1997 |
Perinatal complications and abnormal proton metabolite concentrations in frontal cortex of adolescents seen on magnetic resonance spectroscopy.
Topics: Aspartic Acid; Brain Damage, Chronic; Choline; Creatine; Female; Follow-Up Studies; Frontal Lobe; Hu | 2000 |
Various enzymes involved with putative neurotransmitters. Regional distribution in the brain of deceased mentally normal, chronic schizophrenics or organic brain syndrome patients.
Topics: Acetylcholinesterase; Acetyltransferases; Adolescent; Adult; Age Factors; Aged; Brain; Brain Chemist | 1973 |